AI-generated market updates and breaking coverage across our tracked tickers.
Johnson & Johnson (JNJ) sees modest pre-market gains amid mixed news, including a court-ordered recalculation of damages in the Auris Health case and positive clinical trial results. Our analysis covers the key developments and investment considerations for JNJ.
